Differential effects of progestins on breast tissue enzymes

Maturitas

Volumn 46, Issue SUPPL. 1, 2003, Pages 45-54

  Pasqualini, J R ^a  

^a Institut de Puericulture   (France)

Author keywords

17 Hydroxysteroid dehydrogenase; Breast cancer; Progestin

Indexed keywords

4 HYDROXYTAMOXIFEN; ANTIESTROGEN; AROMATASE; DRUG METABOLITE; DYDROGESTERONE; ENZYME; ENZYME INHIBITOR; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR; ESTRONE; ESTRONE 3 O SULFAMATE; ESTRONE PHOSPHATE; ESTRONE SULFATASE; ESTRONE SULFATE; GESTAGEN; MEDROGESTONE; N BUTYL 11 (3,17BETA DIHYDROXYESTRA 1,3,5(10) TRIEN 7ALPHA YL) N METHYLUNDECANAMIDE; NANDROLONE DERIVATIVE; NOMEGESTROL ACETATE; NORELGESTROMIN; ORG 30 126; ORG 4094; ORG OM 38; PRASTERONE PHOSPHATE; PROGESTERONE; PROMEGESTONE; SULFATASE; SULFOTRANSFERASE; TAMOXIFEN; TAMOXIFEN CITRATE; TESTOSTERONE 17BETA DEHYDROGENASE; TIBOLONE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

BREAST; BREAST CANCER; BREAST CARCINOGENESIS; BREAST CARCINOMA; CANCER CELL CULTURE; CANCER CONTROL; CELL PROLIFERATION; CORRELATION ANALYSIS; DRUG MECHANISM; DRUG POTENCY; DRUG RECEPTOR BINDING; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; ESTROGEN METABOLISM; ESTROGEN SYNTHESIS; HORMONAL REGULATION; HORMONE DEFICIENCY; HORMONE RECEPTOR INTERACTION; HUMAN; HUMAN CELL CULTURE; IC 50; MENOPAUSAL SYNDROME; NONHUMAN; OSTEOPOROSIS; POSTMENOPAUSE; REGULATORY MECHANISM; REVIEW;

EID: 0344737037     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.maturitas.2003.09.018     Document Type: Article

References (59)

1. Loriaux D.L., Ruder H.J., Lipsett M.B. The measurement of estrone sulfate in plasma. Steroids. 18:1971;463-473.
2. Santen RJ, Leszczynski D, Tilson-Mallet N, Feil PD, Wright C, Manni A, Santner SJ. Enzymatic control of estrogen production in human breast cancer: relative significance of aromatase vs. sulfatase pathway. In: Angeli A, Bradlow HL, Dogliotte L, editors. Endocrinology of the breast: basic and clinical aspects, vol. 464. New York, NY: Academic Press; 1986. p. 126-37.
3. Pasqualini J.R., Chetrite G., Blacker M.-C., Feinstein M.-C., Delalonde L., Talbi M., Maloche C. Concentrations of estrone, estradiol, estrone sulfate and evaluation of sulfatase and aromatase activities in pre- and postmenopausal breast cancer patients. J. Clin. Endocrinol. Metab. 81:1996;1460-1464.
4. Vignon F., Terqui M., Westley B., Derocq D., Rochefort H. Effects of plasma estrogen sulfates in mammary cancer cells. Endocrinology. 106:1980;1079-1086.
5. Westley B., Rochefort H. A secreted glycoprotein induced by estrogen in human breast cancer cell lines. Cell. 20:1980;353-362.
6. Pasqualini J.R., Gelly C., Lecerf F. Estrogen sulfates: biological and ultrastructural responses and metabolism in MCF-7 human breast cancer cell. Breast Cancer Res. Treat. 8:1986;233-240.
7. Pasqualini J.R., Gelly C., Lecerf F. Biological effects and morphological responses to estriol-3-sulfate, estriol-17-sulfate and tamoxifen in a tamoxifen-resistant cell line (R-27) derived from MCF-7 human breast cancer cells. Eur. J. Cancer Clin. Oncol. 22:1986;1495-1501.
8. Santner S.J., Ohlsson-Wilhelm B., Santen R.J. Estrone sulfate promotes human breast cancer cell replication and nuclear uptake of estradiol in MCF-7 cell cultures. Eur. J. Cancer. 54:1993;119-124.
9. Chetrite G., Cortes-Prieto J., Philippe J.-C., Wright F., Pasqualini J.R. Comparison of estrogen concentrations, estrone sulfatase and aromatase activities in normal, and in cancerous, human breast tissues. J. Steroid Biochem. Mol. Biol. 72:2000;23-27.
10. Naitoh K., Honjo H., Yamamoto T., Urabe M., Ogino Y., Yasumura T., Nambara T. Estrone sulfate and sulfatase activity in human breast cancer and endometrial cancer. J. Steroid Biochem. 33:1989;1049-1054.
11. Imoto S., Mitani F., Enomoto K., Fujiwara K., Ikeda T., Kitajima M., Ishimura Y. Influence of estrogen metabolism on proliferation of human breast cancer. Breast Cancer Res. Treat. 42:1997;57-64.
12. Pasqualini J.R., Cortes-Prieto J., Chetrite G., Talbi M., Ruiz A. Concentrations of estrone, estradiol and their sulfates, and evaluation of sulfatase and aromatase activities in patients with breast fibroadenoma. Int. J. Cancer. 70:1997;343-369.
13. Pasqualini J.R., Schatz B., Varin C., Nguyen B.-L. Recent data on estrogen sulfatases and sulfotransferases activities in human breast cancer. J. Steroid Biochem. Mol. Biol. 41:1992;323-329.
14. Pasqualini J.R., Chetrite G., Nguyen B.-L., Maloche C., Delalonde L., Talbi M., Feinstein M.-C., Blacker C., Botella J., Paris J. Estrone sulfate-sulfatase and 17β-hydroxysteroid dehydrogenase activities: a hypothesis for their role in the evolution of human breast cancer from hormone-dependence to hormone-independence. J. Steroid Biochem. Mol. Biol. 53:1995;407-412.
15. Pasqualini J.R., Maloche C., Maroni M., Chetrite G. Effect of the progestagen promegestone (R-5020) on mRNA of the oestrone sulphatase in the MCF-7 human mammary cancer cells. Anticancer Res. 14:1994;1589-1594.
16. Pasqualini J.R., Gelly C. Effect of tamoxifen and tamoxifen derivatives on the conversion of estrone-sulfate to estradiol in the MCF-7 and R-27 mammary cancer cell lines. Cancer Lett. 40:1988;115-121.
17. Pasqualini J.R., Giambiagi N., Gelly C., Chetrite G. Antiestrogen action in mammary cancer and in fetal cells. J. Steroid Biochem. Mol. Biol. 37:1990;343-348.
18. Pasqualini J.R., Nguyen B.-L. Estrone sulfatase activity and effect of antiestrogens on transformation of estrone sulfate in hormone-dependent vs. independent human breast cancer cell lines. Breast Cancer Res. Treat. 18:1991;93-98.
19. Santner S.J., Santen R.J. Inhibition of estrone sulfatase and 17β-hydroxysteroid dehydrogenase by antiestrogens. J. Steroid Biochem. Mol. Biol. 45:1993;383-390.
20. Chu G.H., Peters A., Selcer K.W., Li A., Peters P.K. Synthesis and sulfatase inhibitory activities of (E)- and (Z)-4-hydroxytamoxifen sulfamates. Bioorg. Med. Chem. Lett. 18:1999;141-144.
21. Pasqualini J.R., Varin C., Nguyen B.-L. Effect of the progestagen R5020 (promegestone) and of progesterone on the uptake and on the transformation of estrone sulfate in the MCF-7 and T-47D human mammary cancer cells: correlation with progesterone receptor levels. Cancer Lett. 66:1992;55-60.
22. Chetrite G., Paris J., Botella J., Pasqualini J.R. Effect of nomegestrol actetate on estrone sulfatase and 17β-hydroxysteroid dehydrogenase activities in human breast cancer cells. J. Steroid Biochem. Mol. Biol. 58:1996;525-531.
23. Chetrite G., Ebert C., Wright F., Philippe J.-C., Pasqualini J.R. Control of sulfatase and sulfotransferase activities by medrogestone in the hormone-dependent MCF-7 and T-47D human breast cancer cell lines. J. Steroid Biochem. Mol. Biol. 70:1999;39-45.
24. Pasqualini JR, Caubel P, Friedman AJ, Philippe J-C, Chetrite GS. Norelgestromin as selective estrogen enzyme modulator in human breast cancer cell lines. Effect on sulfatase activity in comparison to medroxyprogesterone acetate. J Steroid Biochem Mol Biol 2003;84:193-198.
25. ®) and its 20-dihydro-derivative as selective estrogen enzyme modulators in human breast cancer cell lines. Effects on sulfatase and on 17β-hydroxysteroid dehydrogenase (17β-HSD) activity. Anticancer Res. 2004, in press.
26. Chetrite G.S., Kloosterboer H.J., Pasqualini J.R. Effect of tibolone (Org OD14) and its metabolites on estrone sulphatase activity in MCF-7 and T-47D mammary cancer cells. Anticancer Res. 17:1997;135-140.
27. Selcer K.W., Li P.-K. Estrogenicity, antiestrogenecity and estrone sulfatase inhibition of estrone-3-amine and estrone-3-thiol. J. Steroid Biochem. Mol. Biol. 52:1995;281-286.
28. Howarth N.M., Purohit A., Reed M.J., Potter B.V.L. Estrone sulfamates: potent inhibitors of estrone sulfatase with therapeutic potential. J. Med. Chem. 37:1994;219-221.
29. Purohit A., Williams G.J., Roberts C.J., Potter B.V.L., Reed M.J. In vivo inhibition of oestrone sulphatase and dehydroepiandrosterone sulphatase by oestrone-3-O-sulphamate. Int. J. Cancer. 63:1995;106-111.
30. Elger W., Schwarz S., Hedden A., Reddersen G., Schneider B. Sulfamates of various estrogens are prodrugs with increased systemic and reduced hepatic estrogenicity at oral application. J. Steroid Biochem. Mol. Biol. 55:1995;395-403.
31. Valigora S.D., Li P.-K., Dunphy G., Turner M., Ely D.L. Steroid sulfatase inhibitor alters blood pressure and steroid profiles in hypertensive rats. J. Steroid Biochem. Mol. Biol. 73:2000;113-122.
32. Anderson C.J., Lucas L.J.H., Widlanski T.S. Molecular recognition in biological systems: phosphate esters vs. sulfate esters and the mechanism of action of steroid sulfatase. J. Am. Chem. Soc. 117:1995;3889-3890.
33. Boivin R.P., Luu-The V., Lachance R., Labrie F., Poirier D. Structure-activity relationships of 17alpha-derivates of estradiol as inhibitors of steroid-sulfatase. J. Med. Chem. 43:2000;4465-4478.
34. Poirier D., Boivin R.P. 17α-Alkyl- or 17α-substituted benzyl-17β-estradiols: a new family of estrone-sulfatase inhibitors. Bioorg. Med. Chem. Lett. 8:1998;1891-1896.
35. Ciobanu L.C., Boivin R.P., Luu-The V., Labrie F., Poirier D. Potent inhibition of steroid sulfatase activity by 3-O-sulfamate 17α-benzyl (or 4-tert-butylbenzyl)estra-1,3,5(10)-trienes: combination of two substituents at positions C3 and C17α of estradiol. J. Med. Chem. 42:1999;2280-2286.
36. Purohit A., Vernon K.A., Hummelinck A.E.W., Woo L.W., Hejaz H.A., Potter B.V., Reed M.J. The development of a-ring modified analogues of oestrone-3-O-sulphamate as potent steroid sulphatase inhibitors with reduce oestrogenecity. J. Steroid Biochem. Mol. Biol. 64:1998;269-276.
37. Purohit A., Woo L.W.L., Barrow D., Hejaz H.A., Nicholson R.I., Potter B.V., Reed M.J. Non-steroidal and steroidal sulfamates: new drugs for cancer therapy. Mol. Cell Endocr. 171:2001;129-135.
38. Malini B., Purohit A., Ganeshapillai D., Woo L.W.L., Potter B.V.L., Reed M.J. Inhibition of steroid sulphatase activity by tricyclic coumarin sulphamates. J. Steroid Biochem. Mol. Biol. 75:2000;253-258.
39. Woo L.W.L., Lightowler M., Purohit A., Reed M.J., Potter B.V.L. Heteroatom-substituted analogues of the active-site directed inhibitor estra-1,3,5(10)-trien-17-one-3-sulphamate inhibit estrone sulphatase by a different mechanism. J. Steroid Biochem. Mol. Biol. 57:1996;79-88.
40. Woo L.W.L., Purohit A., Malini B., Reed M.J., Potter B.V.L. Potent active site-directed inhibition of steroid sulphatase by tricyclic coumarin-based sulphamates. Chem. Biol. 7:2000;773-791.
41. Pasqualini J.R., Chetrite G. Paradoxical effect of estradiol: it can block its own bioformation in human breast cancer cells. J Steroid Biochem. Mol. Biol. 78:2001;21-24.
42. Pollow K., Boquoi E., Baumann J., Schmidt-Gollwitzer M., Pollow B. Comparison of the in vitro conversion of estradiol-17β to estrone of normal and neoplastic human breast tissue. Mol. Cell Endocr. 6:1977;333-348.
43. Miettinen M., Mustonen M., Poutanen M., Isomaa V., Wickman M., Soderqvist G., Vihko R., Vihko P. 17β-hydroxysteroid dehydrogenases in normal human mammary epithelial cells and breast tissue. Breast Cancer Res. Treat. 57:1999;175-182.
44. Poutanen M., Moncharmont B., Vihko R. 17β-Hydroxysteroid dehydrogenase gene expression in human breast cancer cells: regulation of expression by a progestin. Cancer Res. 52:1992;290-294.
45. Bonney R.C., Reed M.J., Davidson K., Beranek P.A., James V.H.T. The relationship between 17β-hydroxysteroid dehydrogenase activity and oestrogen concentrations in human breast tumours and in normal breast tissue. Clin. Endocr. 19:1983;727-739.
46. Couture P., Theriault C., Simard J., Labrie F. Androgen receptor-mediated stimulation of 17β-hydroxysteroid dehydrogenase activity by dihydrotestosterone and medroxyprogesterone acetate in ZR-75-1 human breast cancer cells. Endocrinology. 132:1993;179-185.
47. Nguyen B.-L., Chetrite G., Pasqualini J.R. Transformation of estrone and estradiol in hormone-dependent and hormone-independent human breast cancer cells. Breast Cancer Res. Treat. 34:1995;139-146.
48. Peltoketo H., Isomaa V.V., Poutanen M.H., Vihko R. Expression and regulation of 17β-hydroxysteroid dehydrogenase type 1. J. Endocrinol. 150:1996;S21-S30.
49. Prudhomme J.F., Malet C., Gompel A., Lalardie J.P., Ochoa C., Boue A., Mauvais-Jarvis P., Kuttenn F. 17β-Hydroxysteroid dehydrogenase activity in human breast epithelial cells and fibroblast cultures. Endocrinology. 114:1984;1483-1489.
50. Gompel A., Malet C., Spritzer P., Lalardrie J.-P., Kuttenn F., Mauvais-Jarvis P. Progestin effect on cell proliferation and 17β-hydroxysteroid dehydrogenase activity in normal human breast cells in culture. J. Clin. Endocrinol. Metab. 63:1986;1174-1180.
51. Coldham N.G., James V.H.T. A possible mechanism for increased breast cell proliferation by progestins through increased reductive 17β-hydroxysteroid dehydrogenase activity. Int. J. Cancer. 45:1990;174-178.
52. Adams E.F., Coldham N.G., James V.H.T. Steroidal regulation of oestradiol-17β-dehydrogenase activity of the human breast cancer cell line MCF-7. J. Endocrinol. 118:1988;149-154.
53. McNeill J.M., Reed M.J., Beranek P.A., Newton C.J., Ghilchik M.W., James V.H.T. The effect of epidermal growth factor, transforming growth factor and breast tumour homogenates on the activity of oestradiol 17β-hydroxysteroid dehydrogenase in cultured adipose tissue. Cancer Lett. 31:1986;213-219.
54. Malet C., Vacca A., Kuttenn F., Mauvais-Jarvis P. 17β-Estradiol dehydrogenase (E2DH) activity in T47D cells. J. Steroid Biochem. Mol. Biol. 39:1991;769-775.
55. Chetrite G.S., Ebert C., Wright F., Philippe J.-C., Pasqualini J.R. Effect of medrogestone on 17β-hydroxysteroid dehydrogenase activity in the hormone-dependent MCF-7 and T-47D human breast cancer cell lines. J. Steroid Biochem. Mol. Biol. 68:1999;51-56.
56. Qian Y., Deng C., Song W.-C. Expression of estrogen sulfotransferase in MCF-7 cells by cDNA transfection suppresses the estrogen response: potential role of the enzyme in regulating estrogen-dependent growth of breast epithelial cells. J. Pharmacol. Exp. Ther. 2:1988;555-560.
57. Falany J.L., Falany C.N. Expression of cytosolic sulfotransferases in normal mammary epithelial cells and breast cancer cell lines. Cancer Res. 56:1996;1551-1555.
58. Falany J.L., Falany C.N. Regulation of estrogen activity by sulfation in human MCF-7 human breast cancer cells. Oncol. Res. 9:1997;589-596.
59. Chetrite G.S., Pasqualini J.R. The selective estrogen enzyme modulator (SEEM) in breast cancer. J. Steroid Biochem. Mol. Biol. 76:2001;95-104.